ストックスクリーナーアプリを入手
1.92
3.03%
-0.06
アフターアワーズ：
1.92
前日終値:
$1.98
開ける：
$2
24時間の取引高:
97,958
Relative Volume:
0.03
時価総額：
$28.80M
収益：
$130.00K
当期純損益:
$-19.22M
株価収益率:
-1.0134
EPS:
-1.8946
ネットキャッシュフロー:
$-18.01M
1週間 パフォーマンス:
+19.25%
1か月 パフォーマンス:
-2.54%
6か月 パフォーマンス:
-50.90%
1年 パフォーマンス:
-67.18%
1日の値動き範囲:
$1.8515
$2.00
1週間の範囲:
$1.5502
$2.03
52週間の値動き範囲:
$1.22
$7.92
Serina Therapeutics Inc Stock (SER) Company Profile
Compare SER vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
1.92 | 29.70M | 130.00K | -19.22M | -18.01M | -1.8946 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-14 | 開始されました | H.C. Wainwright | Buy |
Serina Therapeutics Inc (SER) 最新ニュース
Director boosts stake in Serina Therapeutics (SER) with 20K-share buy - Stock Titan
Serina Therapeutics Inc (SER) Q1 2026 Earnings: EPS Miss Amid Continued Development ProgressFinancial Summary - Newser
Serina Therapeutics Q1 2026 Earnings: EPS Misses Estimates as Stock Climbs Despite LossGAAP Earnings Report - Newser
Serina Therapeutics Inc. (SER) Recovers 4.93% as Stock Approaches Key Resistance at $2.08Volume Spike Alerts - Newser
Serina Therapeutics Inc. (SER) Gains Nearly 5% as Stock Approaches Key ResistanceTop Analyst Buy Signals - Newser
Director at Serina Therapeutics (SER) makes open-market buy of 12,183 shares - Stock Titan
16.45M Serina shares registered for resale (NYSE: SER) - Stock Titan
Serina Therapeutics : Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi - marketscreener.com
SER Stock Price, Quote & Chart | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
Serina Therapeutics (SER) Gets a Buy from JonesTrading - The Globe and Mail
Insider-Backed PIPE Deal May Dilute Serina Therapeutics Shareholders and Heighten Governance Risks - The Globe and Mail
Serina Therapeutics (SER) stock surges over 39% after hours—here's why - MSN
Serina Therapeutics 1Q Loss/Shr 58c >SER - Moomoo
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Parkinson's drug trial moves ahead as Serina adds $21.2M funding - Stock Titan
Serina Therapeutics (NYSE: SER) raises $21.2M and advances SER-252 trial - Stock Titan
Serina Therapeutics (NYSE: SER) posts Q1 loss and raises $21.2M PIPE amid cash risk - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
SER Technical Analysis | Trend, Signals & Chart Patterns | SERINA THERAPEUTICS INC. (NYSEARCA:SER) - ChartMill
MSN Money - MSN
TradingKey - TradingKey
What Serina Therapeutics (SER) is doing to stay ahead (Slight Loss) 2026-05-08Social Trade Signals - newser.com
How Serina Therapeutics (SER) responds when competition intensifies (Volatility Increases) 2026-05-08Community Buy Alerts - newser.com
The recurring revenue story behind Serina Therapeutics (SER) | Q4 2025: EPS Exceeds ExpectationsPut/Call Ratio - newser.com
Sio Capital (SER) reports 1,000,000 shares, 6.71% stake in Serina Therapeutics - Stock Titan
Serina Therapeutics (SER) Stock: Is It a Strong Investment Pick | Q4 2025: Earnings Beat EstimatesTrending Entry Points - newser.com
Chart Pattern Insight | Serina Therapeutics notches 33% EPS beat, tops loss estimatesPost Earnings - newser.com
Serina Therapeutics (NYSE: SER) seeks share increase and equity plan changes in 2026 proxy - Stock Titan
Serina Therapeutics Updates Executive Leadership and Governance Structure - The Globe and Mail
Serina Therapeutics Inc (SER) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):